Feng Ye

525 total citations
17 papers, 273 citations indexed

About

Feng Ye is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Feng Ye has authored 17 papers receiving a total of 273 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Molecular Biology, 6 papers in Oncology and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Feng Ye's work include Lung Cancer Treatments and Mutations (3 papers), DNA Repair Mechanisms (2 papers) and Colorectal Cancer Treatments and Studies (2 papers). Feng Ye is often cited by papers focused on Lung Cancer Treatments and Mutations (3 papers), DNA Repair Mechanisms (2 papers) and Colorectal Cancer Treatments and Studies (2 papers). Feng Ye collaborates with scholars based in China, United States and Germany. Feng Ye's co-authors include Xiaoting Lin, Wen Liu, Guo-Sheng Hu, Yi Jia, Shiwen Zhuang, Xi Luo, Jun Du, Chen Xue, Lei Wang and Jian‐cheng Ding and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Feng Ye

13 papers receiving 270 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Feng Ye China 7 179 101 45 43 31 17 273
Binbin Cui China 12 197 1.1× 123 1.2× 56 1.2× 34 0.8× 28 0.9× 20 340
Jiyoung Yu South Korea 10 185 1.0× 49 0.5× 39 0.9× 26 0.6× 13 0.4× 25 332
Hanzhi Ling China 8 194 1.1× 90 0.9× 58 1.3× 18 0.4× 92 3.0× 9 333
Yuanming Zou China 8 227 1.3× 89 0.9× 25 0.6× 12 0.3× 41 1.3× 14 363
Mark deCaestecker United States 6 183 1.0× 26 0.3× 23 0.5× 47 1.1× 10 0.3× 9 270
Rimpi Khurana United States 6 180 1.0× 104 1.0× 22 0.5× 28 0.7× 6 0.2× 9 242
Tianyu Qu China 9 221 1.2× 117 1.2× 49 1.1× 5 0.1× 23 0.7× 16 305
Megan Stevens United Kingdom 9 198 1.1× 40 0.4× 19 0.4× 12 0.3× 72 2.3× 17 312

Countries citing papers authored by Feng Ye

Since Specialization
Citations

This map shows the geographic impact of Feng Ye's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Feng Ye with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Feng Ye more than expected).

Fields of papers citing papers by Feng Ye

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Feng Ye. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Feng Ye. The network helps show where Feng Ye may publish in the future.

Co-authorship network of co-authors of Feng Ye

This figure shows the co-authorship network connecting the top 25 collaborators of Feng Ye. A scholar is included among the top collaborators of Feng Ye based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Feng Ye. Feng Ye is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Zhou, Jingwen, Renxian Gao, Hongmei Li, et al.. (2025). Breath Analysis Based on Advanced Photoinduced Charge Transfer Resonance-Assisted Strategy for Oxidative Stress Monitoring. Analytical Chemistry. 97(38). 20908–20917.
2.
Deng, Ting, Yuxian Bai, Tianshu Liu, et al.. (2025). Paclitaxel oral solution versus paclitaxel injection as a second-line therapy in advanced gastric cancer: A randomized, open-label, non-inferiority phase 3 trial.. Journal of Clinical Oncology. 43(4_suppl). 442–442. 1 indexed citations
3.
Sun, Zhihong, et al.. (2025). Ninjurin-1 drives atherosclerosis progression via NF-κB/CXCL-8 activation in endothelial cells. Frontiers in Immunology. 16. 1676216–1676216.
4.
Jiang, Beibei, Xiang Zhang, Wenguang He, et al.. (2025). The prognostic and predictive value of homologous recombination deficiency in gastrointestinal cancer. The Oncologist. 30(6). 3 indexed citations
5.
6.
Ye, Feng, Zhengzhe Li, Heather Wang, et al.. (2024). HIPK2 C-terminal domain inhibits NF-κB signaling and renal inflammation in kidney injury. JCI Insight. 9(8). 2 indexed citations
7.
Wu, Jingxun, et al.. (2024). ALYREF recruits ELAVL1 to promote colorectal tumorigenesis via facilitating RNA m5C recognition and nuclear export. npj Precision Oncology. 8(1). 243–243. 11 indexed citations
8.
Zhao, Wenjuan, Yi Liu, Mengdi Zhang, et al.. (2024). Lipid safety of tenofovir alafenamide during 96-week treatment in treatment-naive chronic hepatitis B patients. Frontiers in Medicine. 11. 1399665–1399665. 2 indexed citations
9.
10.
Fang, Wenfeng, Qiming Wang, Ying Cheng, et al.. (2024). Sacituzumab tirumotecan (SKB264/MK-2870) in combination with KL-A167 (anti-PD-L1) as first-line treatment for patients with advanced NSCLC from the phase II OptiTROP-Lung01 study.. Journal of Clinical Oncology. 42(16_suppl). 8502–8502. 10 indexed citations
11.
12.
Wang, Zhenghang, Lin Shen, Lin Wu, et al.. (2024). Phase 1 study of ERK inhibitor JSI-1187 for patients with advanced solid tumors with MAPK pathway mutations.. Journal of Clinical Oncology. 42(16_suppl). e15111–e15111.
13.
Wang, Xinwei, Mu Wang, Feng Ye, et al.. (2023). Structural insights into dimerization and activation of the mGlu2–mGlu3 and mGlu2–mGlu4 heterodimers. Cell Research. 33(10). 762–774. 31 indexed citations
14.
Lin, Xiaoting, Shiwen Zhuang, Chen Xue, et al.. (2021). lncRNA ITGB8-AS1 functions as a ceRNA to promote colorectal cancer growth and migration through integrin-mediated focal adhesion signaling. Molecular Therapy. 30(2). 688–702. 104 indexed citations
15.
Chen, Anqun, Feng Ye, Han Lai, et al.. (2020). Soluble RARRES1 induces podocyte apoptosis to promote glomerular disease progression. Journal of Clinical Investigation. 130(10). 5523–5535. 65 indexed citations
16.
Zhu, Yongjun, Hongwang Cui, Jie Lv, et al.. (2020). Angiotensin II triggers RIPK3-MLKL-mediated necroptosis by activating the Fas/FasL signaling pathway in renal tubular cells. PLoS ONE. 15(3). e0228385–e0228385. 17 indexed citations
17.
Xia, Lu, Yixing Chen, Jiani Zheng, et al.. (2019). Aldolase B impairs DNA mismatch repair and induces apoptosis in colon adenocarcinoma. Pathology - Research and Practice. 215(11). 152597–152597. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Binbin Cui Breakdown of academic impact, for papers by Jiyoung Yu Breakdown of academic impact, for papers by Hanzhi Ling Breakdown of academic impact, for papers by Yuanming Zou Breakdown of academic impact, for papers by Mark deCaestecker Breakdown of academic impact, for papers by Rimpi Khurana Breakdown of academic impact, for papers by Tianyu Qu Breakdown of academic impact, for papers by Megan Stevens
Rankless by CCL
2026